Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Hypoxic-ischemic encephalopathy
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Mar 27, 2025
Neuren initiates development of NNZ-2591 to treat HIE
Mar 27, 2025
Update - Notification of buy-back - NEU
Mar 26, 2025
Update - Notification of buy-back - NEU
Mar 25, 2025
Update - Notification of buy-back - NEU
Mar 24, 2025
Update - Notification of buy-back - NEU
Mar 21, 2025
Update - Notification of buy-back - NEU
Mar 20, 2025
Update - Notification of buy-back - NEU
Mar 19, 2025
Update - Notification of buy-back - NEU
Mar 18, 2025
Update - Notification of buy-back - NEU
Mar 17, 2025
Update - Notification of buy-back - NEU
1
2
3
4
Next
